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Abstract
Objective—To determine the short-term outcome of neuropsychiatric (NP) events upon 
enrollment into an international, inception cohort of SLE patients.
Methods—The study was performed by the Systemic Lupus International Collaborating Clinics. 
Patients were enrolled within 15 months of diagnosis of SLE and NP events were characterized 
using the ACR case definitions. Decision rules were derived to identify NP events attributable to 
SLE. Physician outcome scores of NP events and patient derived mental (MCS) and physical 
(PCS) component summary scores of the SF-36 were recorded.
Results—There were 890 patients (88.7% female) with a mean (± SD) age of 33.8 ± 13.4 years 
and mean disease duration of 5.3 ± 4.2 months. Within the enrollment window 271/890 (33. 5%) 
patients had at least 1 NP event encompassing 15 NP syndromes. NP events attributed to SLE 
varied from 16.5% – 33.9% using alternate attribution models and occurred in 6.0% – 11.5% of 
patients. Outcome scores for NP events attributed to SLE were significantly better than for NP 
events due to non-SLE causes. Higher global disease activity was associated with worse outcomes. 
MCS scores were lower in patients with NP events, regardless of attribution, and were also lower 
in patients with diffuse and central NP events. There was a significant association between 
physician outcome scores and patient MCS scores only for NP events attributed to SLE.
Conclusion—In SLE patients the short-term outcome of NP events is determined by both the 
characteristics and attribution of the events.
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Nervous system disease is well recognized in systemic lupus erythematosus (SLE) and 
comprises both neurologic (N) and psychiatric (P) manifestations. Individual 
neuropsychiatric (NP) presentations include common disorders such as headaches, 
depression and cerebrovascular disease in addition to less common entities such as seizures, 
psychosis and demyelination [1–6]. In view of the non-specific nature of many of the NP 
syndromes, it is likely that some of the NP events in SLE patients are not a primary 
manifestation of the disease but rather occur due to complications of SLE, its therapy or a 
concurrent disease process [3, 4]. Regardless of attribution, the clinical significance of NP 
disease in SLE patients is reflected by the adverse impact on health-related quality of life [3, 
4] and mortality [7–9].
There is relatively little information on the short or long-term outcome of NP events in SLE. 
Previous studies [10–16] have been limited by their small sample size and variable disease 
duration in individual patients, exclusion of NP events which were not attributable to SLE 
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and restriction to individual NP manifestations rather than including the totality of possible 
NP events. We have assembled an international, multi-center, disease inception cohort of 
SLE patients and identified all NP events occurring at the time of diagnosis of SLE using 
standardized case definitions. In this study we report the short-term outcome of these NP 
events. In addition, several clinical variables, including the characteristics and attribution of 
events to SLE or non-SLE causes, patient demographics and global SLE disease activity 
were examined for association with improvement or deterioration in NP status.
Patients and Methods
Research study network
The study was conducted by the Systemic Lupus International Collaborating Clinics 
(SLICC) [17] which consists of 27 academic medical centres in eight countries with 30 
investigators. SLICC centres were grouped into geographic locations (Canada, U.S.A./
Mexico, Europe, and Asia). Data were collected prospectively on patients presenting with a 
new diagnosis of SLE. All information was submitted to the coordinating centre in Halifax, 
Nova Scotia, Canada. Additional information on the same patients was collected 
concurrently in a study of atherosclerosis in SLE and submitted to the coordinating centre at 
the University of Toronto, Ontario, Canada. Electronic data transfer occurred between the 
Toronto and Halifax sites and the merged dataset was available for analysis. The study 
protocol was approved by the Capital Health Research Ethics Board, Halifax, Nova Scotia, 
Canada and by each of the participating centre’s own institutional research ethics review 
boards in accordance with the Declaration of Helsinki’s guidelines for research in humans.
Patients
All patients fulfilled the ACR classification criteria for SLE [18] and provided written 
informed consent. The date of diagnosis was the time when at least four of the cumulative 
ACR criteria were first recognized. Enrollment in the study was encouraged as close as 
possible to the date of diagnosis but was permitted for up to 15 months following the 
diagnosis. Data included age, gender, ethnicity, education and medication history. Lupus-
related variables included the ACR classification criteria for SLE [18], the SLE Disease 
Activity Index (SLEDAI) [19] and the SLICC/ACR damage index (SDI) [20]. Laboratory 
data included a complete blood count, serum creatinine, urinalysis and immunologic 
variables required for SLEDAI and SDI scores. Health related quality of life (HRQOL) was 
measured by the SF-36 [21].
Neuropsychiatric (NP) events
An enrollment window was defined within which all NP events, some of which are 
inherently evanescent, were captured. To ensure inclusion of NP events which may have 
been part of the presentation of lupus but which occurred prior to the accumulation of four 
ACR classification criteria, the enrollment window extended from 6 months prior to the date 
of diagnosis of SLE up to the enrollment date. As the latter could occur up to 15 months 
following the diagnosis of SLE, the maximum duration of the enrollment window was 21 
months. The specific NP events identified were characterized using the ACR nomenclature 
and case definitions for 19 NP syndromes [22] described in SLE. Screening for NP 
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syndromes was done primarily by clinical evaluation and subsequent investigations were 
performed only if clinically warranted. In order to further improve the consistency of data 
collection, a checklist of NP symptoms was distributed to each of the participating sites for 
use during patient encounters. In the majority of cases, the diagnosis of cognitive 
impairment was made on the basis of clinical assessment rather than formal 
neuropsychological testing.
All NP events within the enrollment window were identified and additional information was 
recorded depending upon the type of NP event and guided by the ACR glossary for NP 
syndromes [22]. This included potential etiologic factors other than SLE which were 
considered for exclusion, or recognized as an “association”, acknowledging that it is not 
always possible to be definitive about attribution. Collectively, these “exclusions” and 
“associations” were referred to as “non-SLE factors” and used in part to determine the 
attribution of NP events. Patients could have more than one type of NP event but repeated 
episodes of the same event occurring within the enrollment window were recorded only 
once. In the latter case the time of the first episode was taken as the date of onset of the NP 
event.
Attribution of NP events
Participating centres reported all NP events regardless of etiology. Decision rules were 
derived to determine the attribution of NP events which occurred within the enrollment 
window. Factors which were taken into account included: (i) onset of NP event(s) prior to 
study enrollment; (ii) presence of concurrent non-SLE factor(s) which were identified as part 
of the ACR definitions for each NP syndrome and considered to be a likely cause or 
significant contributor to the event and (iii) occurrence of “minor” NP events as defined by 
Ainiala et al who have previously reported a high frequency of such events in normal 
population controls [1]. These include all headaches, anxiety, mild depression (i.e. all mood 
disorders which fail to meet the criteria for “major depressive-like episodes”), mild cognitive 
impairment (deficits in less than 3 of the 8 specified cognitive domains) and polyneuropathy 
without electrophysiological confirmation.
The attribution of NP events to SLE was determined by two sets of decision rules (model A 
and B) of different stringency as described in detail elsewhere [4]. NP events which fulfilled 
the criteria for model A (the most stringent) or for model B (the least stringent) were 
attributed to SLE. Those NP events which did not fulfill these criteria were attributed to non-
SLE causes:
Attribution Model A: NP events which had their onset within the enrollment window 
and had no “exclusions” or “associations” and were not one of the NP events 
identified by Ainiala [1] were attributed to SLE.
Attribution Model B: NP events which had their onset within 10 years of the 
diagnosis of SLE and had no “exclusions” and were not one of the NP events 
identified by Ainiala [1] were attributed to SLE.
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Outcome of NP events
Two outcome measures of NP events were used to capture both the physician’s and patient’s 
assessment at study enrollment. These included (i) a physician generated 7-point Likert scale 
for individual NP events comparing the change in the NP status between the onset of the 
event and time of study enrollment (1 = patient demise, 2 = much worse, 3 = worse, 4 = no 
change, 5 = improved, 6 = much improved, 7 = resolved); (ii) patient generated mental 
(MCS) and physical (PCS) component summary scores of the SF-36 [21].
Statistical analysis
Individual NP manifestations were categorized by attribution to either SLE (model A or 
model B) or non-SLE causes. The distribution of patients in this hierarchy, and a no NP 
event class where relevant, was examined for associations with the outcome of the event as 
determined by physician assessment and patient generated SF-36 component summary 
scores. In addition, the NP manifestations were clustered into subgroups for additional 
analyses. Thus, the 19 NP syndromes were categorized into central and peripheral nervous 
system manifestations as previously described [22]. In addition, NP events were categorized 
into diffuse and focal manifestations; diffuse NP syndromes were aseptic meningitis, 
demyelinating syndrome, headache, acute confusional state, anxiety disorder, cognitive 
dysfunction, mood disorder and psychosis. Focal NP syndromes were cerebrovascular 
disease, Guillain Barré syndrome, movement disorder, myelopathy, seizure disorders, 
autonomic neuropathy, mononeuropathy, myasthenia gravis, cranial neuropathy, plexopathy 
and polyneuropathy. Descriptive statistics were used to summarize all variables with 
percentages, mean and standard deviation or median and range where appropriate. The 
relationships between the NP event outcome scores and geographical region, educational 
status, ethnicity, gender, age at diagnosis of SLE, disease duration, SLEDAI scores (with and 
without NP variables) and SDI scores (with and without NP variables) were examined by 
ordinal logistic regression, separately for events in the attribution hierarchy. The estimation 
was accomplished by generalized estimating equations (GEE) with an independence 
working correlation structure in order to adjust for multiple events within patients. In 
addition, we defined a time to case resolution variable for the NP events (i.e. NP event score 
= 7), and used Kaplan-Meier estimates and log rank tests to investigate the relationships 
between this event time variable and the time-invariant demographic variables for the 
attribution hierarchy. For SF-36 mental (MCS) and physical (PCS) component summary 
scores, separate analyses by linear regression were used for pre-defined groups: patients 
without NP events; patients with any attributable NP events in model A or in model B and 
patients with non-SLE NP events. The same attribution classification was used in the linear 
regression analyses that examined the association between physician generated NP outcome 
scores and patient generated SF-36 summary scores.
Results
Patients
A total of 890 patients were recruited in 24 centres between October 1999 and November 
2006. The median (range) number of patients enrolled in each centre was 23 (2–104). The 
patients were predominantly women (88.7%), with a mean (± SD) age of 33.8 ± 13.4 years 
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and a wide ethnic distribution although predominantly Caucasian (Table 1). At enrollment 
the mean disease duration was only 5.3 ± 4.2 months. The prevalence of individual ACR 
classification criteria reflected an unselected patient population. The mean SLEDAI and SDI 
scores revealed moderate global disease activity and minimal cumulative organ damage 
respectively. Therapy at the time of enrollment reflected the typical range of lupus 
medications. The mean duration of followup, representing the interval between the time of 
onset of NP events within the enrollment window and the date of assessment, was 3.7 ± 3.1 
months.
Neuropsychiatric (NP) manifestations
Within the enrollment window 271/890 (33.5%) patients had at least 1 NP event and 90/890 
(10.1%) had 2 or more events. There were a total of 407 NP events, encompassing 15 of the 
19 NP syndromes (Table 2). The proportion of NP events attributed to SLE varied from 
16.5% – 33.9% using alternate attribution models and occurred in 6.0 % [model A] – 11.5% 
[model B] of patients. Of the 407 NP events 379 (93%) affected the central nervous system 
and 28 (7%) involved the peripheral nervous system. The numbers of diffuse and focal 
events were 318 (78%) and 89 (22%), respectively.
Physician assessment of outcome of NP events
The outcome of individual NP events was examined following group assignment according 
to attribution (Figure 1), adjusting for multiple NP events in 90 (10.1%) patients. NP events 
attributed to SLE using either attribution model A or model B had a significantly better 
outcome compared to patients with NP events not attributed to lupus (p < 0.001). Outcome 
scores were significantly lower in patients with higher SLEDAI scores (including or 
excluding NP variables) (Figure 2) (attribution model A, p = 0.009, 0.017; attribution model 
B, p = 0.001, 0.002). There was no association between outcome scores and geographical 
region, educational status, ethnicity, gender or age of diagnosis demonstrated by ordinal 
logistic regression or the time to event analysis (data not shown). For NP events attributed to 
SLE using model A only, there was a significant association between worse outcome scores 
and shorter disease duration (p = 0.014) which likely indicates that insufficient time had 
elapsed for improvement to occur. For cumulative damage either including or excluding NP 
variables, we were not able to obtain reliable estimates in ordinal logistic regression because 
the data were too sparse to be informative, while time to event analysis indicated that there 
was no evidence of an association between time to case resolution and cumulative damage 
(including or excluding NP variables). Diffuse NP events had poorer outcome scores 
compared to focal NP events (p < 0.001). In subgroup analyses this was only significant for 
diffuse NP events not attributed to SLE (p = 0.019), but there was no evidence that the 
relationships differed across the attribution classes (model B, p = 0.143)
Patient assessment of outcome of NP events
The SF-36 mental (MCS) and physical (PCS) component summary scores were used to 
assess the impact of NP events from the patients’ perspective. Patients with NP events, 
regardless of attribution, had significantly lower (worse) MCS scores compared to patients 
with no NP events (38.46 ± 13.63 vs. 43.04 ± 12.69; p < 0.001). There was no significant 
difference between MCS scores in patients with NP events attributed to SLE (attribution 
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model A or B) and to non-SLE causes (attribution model B: 39.58 ± 14.05 vs. 37.79 
± 13.38; p = 0.363). There was a significant although less profound difference between PCS 
scores in patients with NP events from any cause compared to patients with no NP events 
(attribution model B: 35.29 ±11.83 vs. 37.47 ± 12.05; p = 0.035) although again there was 
no difference in PCS scores in patients with NP events attributed to SLE and to non-SLE 
causes (35.19 ± 12.28 vs. 35.35 ± 11.60; p = 0.927). These findings are comparable to our 
previous report of the first 572 patients enrolled in the cohort [4]. In addition, patients with 
NP events, regardless of attribution and clustered collectively into diffuse manifestations 
with or without concurrent focal NP events, had lower MCS scores compared to patients 
with focal NP events only (35.71 ± 12.85 vs 37.72 ± 13.52 vs 47.09 ± 12.58; p = 0.002) 
(Figure 3). The findings were similar when the analysis was restricted to patients with NP 
events attributed to SLE using either attribution model A (32.92 ± 12.19 vs 40.64 ± 14.49 vs 
47.20 ± 9.83; p = 0.012) or model B (36.21 ± 13.18 vs 36.83 ± 14.43 vs 48.21 ± 11.14; p = 
0.001) (Figure 3). Similarly, patients with central NP events with and without concurrent 
peripheral NP events, regardless of attribution, had lower MCS scores compared to patients 
with peripheral NP events only (35.28 ± 12.22 vs 38.16 ± 13.63 vs 49.51 ± 11.54; p = 
0.020). In patients with NP events there were no significant associations between MCS 
scores and geographical region, educational status, ethnicity, gender, age of diagnosis, 
disease duration, SLEDAI or cumulative damage computed either including or excluding NP 
variables (data not shown).
Agreement between physician assessment of outcome of NP events and patient SF-36 
summary scores
The 271 patients with NP events were stratified according to the physician generated 
outcome scores. In those patients with more than one outcome score due to the occurrence 
of multiple NP events, the lowest (worst) outcome score was used for group assignment. 
Patients were further segregated by attribution of NP events and differences in MCS scores 
and PCS scores were compared (Figure 4). In those patients with NP events attributed to 
SLE (attribution model A or B) there was a significant association between physician 
generated outcome scores and patient generated MCS scores (p < 0.001). Regression 
analysis provided an R-square value of 0.28 indicating that 28% of the variability in MSC 
scores in this group is explicable on the basis of NP event outcome scores. Similar 
associations were not seen for PCS scores in the patients with NP events attributed to SLE 
nor for MCS or PCS scores in patients with NP events not attributed to SLE (Figure 4).
Discussion
Neuropsychiatric events in SLE patients are frequent and varied [1–6], although the majority 
of events are not a primary feature of the disease [3, 4]. Despite the high prevalence of NP 
events, there have been relatively few attempts to determine their clinical outcome over the 
short or long-term [10–16]. In the present study of an international, multi-centre, inception 
cohort of SLE patients, all NP events were identified within a predefined window around the 
time of diagnosis of SLE. The short-term outcome of these events in the context of 
attribution, global disease activity and other clinical variables was examined. The results 
demonstrate that both physicians and patients identify significant group differences in the 
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outcome of NP events when these are stratified by attribution either to SLE or non-SLE 
causes. For patients with NP events due to SLE, there was significant convergence in 
physician and patient assessments.
Open [13, 14, 23, 24] and controlled [12, 15, 25] clinical trials, retrospective [26, 27] and 
prospective [3, 28, 29] observational cohorts and case series [10] have provided information 
on the prognosis of NP events in SLE patients, particularly those events attributed to SLE. 
The conclusions have been inconsistent. For example, increased mortality, which is a crude 
but important outcome of NP disease, has been reported in some studies [7–9] but not in 
others [30–32]. Clinical trials of NP-SLE have been generally favourable [12–15, 23–25], 
although most have examined specific subsets of NP-SLE and lack controls or blinded 
assessment. Observational studies in patients with NP-SLE have also yielded mixed 
findings. Karassa et al [10] examined the prognosis of NP disease in 32 patients hospitalized 
for NP-SLE and followed for 2 years. The outcome was generally favorable with either 
substantial improvement (69%) or stabilization (19%). Likewise, in a five year prospective 
study of cognitive function in SLE [33], the majority of patients did not have a progressive 
decline in cognition, a finding supported by other studies [29, 34–36]. Conversely the 
adverse effect of cumulative NP events in SLE patients is evident from the significantly 
lower scores for HRQOL in SLE [3, 4], more fatigue [3] and more cumulative organ damage 
compared to patients without NP events [4]. Of interest these associations were independent 
of the attribution of the NP events to SLE or to an alternative etiology [3, 4], and did not 
occur in patients with a history of renal disease which was used as a comparator to assess the 
impact of another major organ system [3]. Jonsen et al [11] reported a higher frequency of 
disability in SLE patients with NP disease compared to patients without NP events and the 
general population. Thus, in contrast to the previous studies [12–15, 23–25, 29, 33, 34], 
these later data suggest that NP events in SLE patients, regardless of their etiology and 
attribution, have a negative impact on quality of life.
The current observational study has several novel features. A large inception cohort provides 
sufficient size and diversity to make the findings generalizable, guarantees universally short 
disease duration which limits the chronic psychological effects of the disease process and 
provides more certainty than a retrospective study for determining the correct attribution of 
NP events. A specific objective was to capture all NP events regardless of attribution, in 
order to measure the full impact of NP disease. Two attribution models of different 
stringency were employed based upon a composite of clinical decision rules. The physician 
generated measure demonstrated a significantly better outcome for NP events attributed to 
SLE compared to non-SLE causes which suggests that the former have greater potential for 
reversibility. An additional observation was the association between poor outcome scores 
and active generalized SLE disease activity outside of the nervous system indicating that NP 
disease which occurs in the context of a generalized lupus flare is less likely to improve, at 
least in the short term.
The MCS and PCS scores of the SF-36 were used to assess the patients’ perspective on NP 
events. As previously reported [4] the MCS scores were significantly lower in patients with 
NP events regardless of attribution. In the current study we also found that MCS scores were 
lower in patients with diffuse compared to focal NP disease and furthermore in central 
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compared to peripheral NP disease. An additional new and important finding is a significant 
association between physician and patient assessments of outcome of NP events attributed to 
SLE as indicated by higher or lower MCS scores in patients assigned to groups with high or 
low physician outcome scores respectively. A similar association was not found for PCS 
scores in the same patient groups nor with either MCS or PCS scores in patients with NP 
events not attributed to SLE. This indicates enhanced sensitivity and specificity for changes 
in NP disease attributed to SLE.
There are a number of limitations to the present study. First, restriction of NP syndromes to 
the 19 identified in the ACR case definitions [22] could potentially have excluded other 
forms of nervous system disease. However, this did not emerge as an issue during the 
execution of the study. In fact, four of the 19 NP syndromes were never identified in this 
relatively large inception cohort. Second, formal neuropsychological assessments were not 
performed routinely on all patients, largely for logistical reasons. If included in the study 
protocol this would likely have increased the prevalence of cognitive impairment in our 
cohort, albeit subtle and sub-clinical in the majority of cases. Several cross-sectional and 
longitudinal studies have indicated that such deficits do not adversely affect HRQOL [33, 
37, 38] or lead to long-term, clinically significant neurological sequelae [33–36]. Third, 
although the physician generated outcome was focused specifically on NP events, the patient 
generated outcome was based upon a generic instrument of HRQOL. However, the MCS 
score of the SF-36 performed well and despite the potential to be influenced by other factors 
it reflected a significant amount of the variability in outcome scores for patients with NP 
events attributed to SLE. Finally, this study evaluated only the short-term outcome of NP 
events occurring around the time of diagnosis of SLE. In spite of this limitation there were 
striking differences in the outcome and impact of NP events depending upon their 
characteristics and attribution. These findings inform our understanding of the evolution of 
NP events in SLE patients and how they can best be evaluated in trials of current and future 
therapies.
In summary, we have demonstrated that the short-term outcome of NP events in recently 
diagnosed SLE patients is different depending on the type and attribution of NP events. This 
is true for both physician and patient assessments. Longer followup of this cohort will 
determine the reproducibility of our findings and examine clinical and laboratory variables 
as potential prognostic indicators for the long-term outcome of NP events.
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Physician generated outcome scores at enrollment for NP events attributed to SLE using 
different attribution models A and B and for NP events attributed to non-SLE causes. Those 
NP events which were attributed to SLE using either attribution model A or model B had a 
significantly better outcome compared to patients with NP events not attributed to lupus (p < 
0.001).
Hanly et al. Page 13




















Physician generated outcome scores at enrollment for NP events attributed to SLE using 
either attribution model A (upper panel) and model B (lower panel). Outcome scores were 
significantly lower in patients with higher SLEDAI scores (excluding NP variables). 
Attribution model A, p = 0.017; Attribution model B, p = 0.002.
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Mental component summary (MCS) scores (mean ± SD) at enrollment in patients with NP 
events assigned to groups with diffuse and focal NP disease, diffuse NP disease only and 
focal NP disease only. Regardless of attribution (upper panel), all patients with diffuse/focal 
and diffuse only events had lower MCS scores compared to patients with focal NP events 
only (p = 0.002). The findings were similar when the analysis was restricted to patients with 
NP events attributed to SLE (lower panel) using either attribution model A (p = 0.012) or 
model B (p = 0.001).
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Boxplot of mental component summary (MCS) scores (median and range) and physical 
component summary (PCS) scores (median and range) at enrollment in patients with NP 
events segregated according to physician generated outcome scores. Patients were further 
divided by attribution of NP events and differences in MCS scores and PCS scores were 
compared. Only in patients with NP events attributed to SLE (attribution model A or B) was 
there a significant association between physician generated outcome scores and patient 
generated MCS scores (left upper panel; p < 0.001). Similar associations were not seen for 
PCS scores in the patients with NP events attributed to SLE nor for MCS scores or PCS 
scores in patients with NP events not attributed to SLE (p > 0.050).
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Table 1
Demographic and clinical manifestations of SLE patients
Number of Patients 890
Gender
 Female 746 (88.7%)
 Male 95 (11.3%)








Post secondary education 63.8%
Disease duration (months) (mean ± SD) 5.3 ± 4.2
Number of ACR criteria (mean ± SD) 4.9 ± 1.0
Cumulative ACR manifestations
 Malar rash 36.9%
 Discoid rash 12.0%
 Photosensitivity 39.4%
 Oral/nasopharyngeal ulcers 37.8%
 Serositis 27.6%
 Arthritis 74.0%
 Renal disorder 28.1%
 Neurological disorder 5.8%
 Hematologic disorder 61.7%
 Immunologic disorder 76.6%
 Antinuclear antibody 96.6%
SLEDAI score (mean ± SD) 5.5 ± 5.6
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Table 2
Characteristics of neuropsychiatric syndromes in SLE patients as indicated by the number of NP events and 
their attribution using attribution models
NP events (%) regardless 
of attribution
NP events due to SLE 
(Model A)
NP events due to SLE 
(Model B)
NP events due to non-
SLE causes
Headache 171 (42.0) 0 0 171
Mood disorders 67 (16.5) 3 22 45
Anxiety disorder 26 (6.4) 0 0 26
Cerebrovascular disease 23 (5.7) 8 22 1
Cognitive dysfunction 26 (6.4) 5 16 10
Seizure disorder 30 (7.4) 16 26 4
Acute confusional state 16 (3.9) 8 13 3
Polyneuropathy 10 (2.5) 3 6 4
Psychosis 9 (2.2) 3 8 1
Mononeuropathy 10 (2.5) 7 10 0
Cranial neuropathy 7 (1.7) 5 5 2
Aseptic meningitis 3 (0.7) 2 2 1
Myelopathy 5 (1.2) 4 5 0
Movement disorder 3 (0.7) 2 2 1
Autonomic disorder 1 (0.3) 1 1 0
Guillain-Barre syndrome 0 0 0 0
Demyelinating syndrome 0 0 0 0
Myasthenia gravis 0 0 0 0
Plexopathy 0 0 0 0
Total 407 67 138 269
*
The attribution of NP events to SLE was determined by two sets of decision rules of different stringency. NP events which fulfilled the criteria for 
Model A (the most stringent) or for Model B (the least stringent) were attributed to SLE. Those events which did not fulfill these criteria were 
attributed to non-SLE causes:
Attribution Model A: NP events which had their onset within the enrollment window and had no “exclusions” or “associations” and were 
not one of the NP events identified by Ainiala [1] were attributed to SLE.
Attribution Model B: NP events which had their onset within 10 years of the diagnosis of SLE and had no “exclusions” and were not one 
of the NP events identified by Ainiala [1] were attributed to SLE.
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